Emerging Treatment Options for Recurrent C. Difficile Infection
EP. 1: C. difficile and C. difficile Infection (CDI) Overview and Risk Factors for CDI
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS A gastroenterologist, Dr. Paul Feuerstadt, provides an overview of C. difficile infection (CDI) and vegetative and spore phases of CDI.
EP. 2: Risk Factors for Primary and Recurrent C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs Lodise and Feuerstadt discuss risk factors for C. difficile infection (CDI).
EP. 3: Timely Referral and Diagnosis of C. Difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs. Abraham, Chopra and Feuerstadt discuss importance of timely referral and diagnostic methods to discern C. difficile infection (CDI).
EP. 4: Preventative Measures for C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Dr. Chopra shares multipronged approach to reducing C. difficile infection (CDI) and the role of antimicrobial stewardship.
EP. 5: Educational Opportunities to Combat C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs. Lodise and Feuerstadt discuss educational opportunities to combat and reduce C. difficile infection (CDI).
EP. 6: Inflammatory Bowel Disease and C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS A gastroenterologist, Dr. Bincy Abraham, provides an overview of C. difficile infection (CDI) in patients with inflammatory bowel disease (IBD).
EP. 7: Diagnosis and Management of C. difficile Infection (CDI) in Patients with Inflammatory Bowel Disease
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Dr. Abraham discusses importance of differential diagnosis of C. difficile infection (CDI) in patients with IBD and how both IBD and CDI should be managed.
EP. 8: Gut Microbiota and Consequences of Gut Microbiota Disruption
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Dr. Tom Lodise provides an overview of gut microbiota and the consequences of dysbiosis.
EP. 9: Long-Term Impact of C. difficile Infection (CDI) and Infection Recurrence
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS A gastroenterologist reviews the long-term impact of dysbiosis and Clostridioides difficile infection.
EP. 10: Treatment Options for C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.
EP. 11: Fecal Microbiota Transplantation (FMT) for Treatment of C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs Tom Lodise and Bincy Abraham provide an overview of fecal microbiota transplantation and long-term safety of FMT use.
EP. 12: Monitoring Patients with C. difficile Infection (CDI) and rCDI
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Dr Teena Chopra shares her approach to monitoring patients with C difficile infection (CDI).
EP. 13: Foundational Trials for Fecal Microbiota Transplantation for C. difficile Infection
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Dr Lodise summarizes foundational trials that led to the use of fecal microbiota transplant for the treatment of rCDI.
EP. 14: Challenges with Current Treatments and Emerging Treatments for C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs Chopra and Feuerstadt summarize challenges with current treatments and discuss live biotherapeutic products that are being studied for recurrent C difficile infection (rCDI).
EP. 15: RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
EP. 16: SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
EP. 17: Differences between Fecal Microbiota Transplantation Studies to Treat C. difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Experts discuss differences in designs of clinical trials of 4 emerging microbiota-based live biotherapeutics - RBX2660, SER-109, CP101, VE303, for treatment of rCDI.
EP. 18: Unmet Needs in Management of C. Difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Teena Chopra, MD, MPH,Bincy Abraham, MD, MS Bincy Abraham, MD, MS; Thomas Lodise, PharmD, PhD; Teena Chopra, MD, MPH; and Paul Feuerstadt, MD, share unmet needs, including access to therapies, in treatment of C. difficile infection (CDI).
EP. 19: Advice for Physicians to Manage C. Difficile Infection (CDI)
ByPaul Feuerstadt, MD, FACG, AGAF,Thomas Lodise, PharmD, PhD,Bincy Abraham, MD, MS,Teena Chopra, MD, MPH Experts share advice for physicians taking care of patients with C. difficile infection (CDI).
